1-amino-cyclopentanecarboxylic acid amide hydrochloride salt | 17704-76-6

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-amino-cyclopentanecarboxylic acid amide hydrochloride salt
• 英文别名: 1-amino-cyclopentanecarboxylic acid amide hydrochloride；1-aminocyclopentanecarboxamide hydrochloride；aminocyclopentane carboxamide hydrochloride；1-Aminocyclopentane-1-carboxamide hydrochloride；1-aminocyclopentane-1-carboxamide;hydrochloride
• CAS: 17704-76-6
• 化学式: C₆H₁₂N₂O*ClH
• mdl: MFCD18838831
• 分子量: 164.635
• InChiKey: UWOSAUYDOGPYDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.37
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  69.1
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-amino-cyclopentanecarboxylic acid amide hydrochloride salt 在 palladium on activated charcoal 盐酸 、 4-二甲氨基吡啶 、 氢气 、 sodium hydride 、 N,N-二异丙基乙胺 、 bromo-tris(1-pyrrolidinyl)phosphonium hexafluorophosphate 、 碘甲烷 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、206.84 kPa 条件下， 反应 101.0h， 生成 (S)-Pyrrolidine-2-carboxylic acid [(R)-1-(1-carbamoyl-cyclopentyl)-2-oxo-pyrrolidin-3-yl]-amide
  参考文献：
  名称：

  Synthesis and Dopamine Receptor Modulating Activity of Novel Peptidomimetics of l-Prolyl-l-leucyl-glycinamide Featuring α,α-Disubstituted Amino Acids

  摘要：

  In the present study, L-prolyl-L-leucyl-glycinamide (1) peptidomimetics 3a-3d and 4a-4d were synthesized utilizing alpha,alpha-disubstituted amino acids. These analogues were designed to explore the conformational effects of constraints at the phi(3) and psi(3) torsion angles. Constrained conformations were verified by the use of X-ray crystallography and circular dichroism. The effects of Pro-Leu-Gly-NH2 analogues 3a-3d and 4a-4d on enhancing rotational behavior induced by apomorphine in the 6-hydroxydopamine-lesioned animal models of Parkinson's disease were studied. The ability of these peptidomimetics to increase the binding of agonist N-propylnorapomorphine (NPA) to the dopamine D-2 receptor was also examined. Extended analogue Pro-Leu-Deg-NH2 was the most active compound of this series. It was 10 times more potent and almost 2 times more effective than 1 in increasing apomorphine-induced rotations (56 +/- 15% at 1.0 mg/kg ip) and in enhancing [H-3]NPA specific binding (40%).

  DOI：

  10.1021/jm980656r
• 作为产物：
  描述：

  (1-氨基甲酰基环戊基)氨基甲酸叔丁酯 在 盐酸 作用下， 生成 1-amino-cyclopentanecarboxylic acid amide hydrochloride salt
  参考文献：
  名称：

  Synthesis and Dopamine Receptor Modulating Activity of Novel Peptidomimetics of l-Prolyl-l-leucyl-glycinamide Featuring α,α-Disubstituted Amino Acids

  摘要：

  In the present study, L-prolyl-L-leucyl-glycinamide (1) peptidomimetics 3a-3d and 4a-4d were synthesized utilizing alpha,alpha-disubstituted amino acids. These analogues were designed to explore the conformational effects of constraints at the phi(3) and psi(3) torsion angles. Constrained conformations were verified by the use of X-ray crystallography and circular dichroism. The effects of Pro-Leu-Gly-NH2 analogues 3a-3d and 4a-4d on enhancing rotational behavior induced by apomorphine in the 6-hydroxydopamine-lesioned animal models of Parkinson's disease were studied. The ability of these peptidomimetics to increase the binding of agonist N-propylnorapomorphine (NPA) to the dopamine D-2 receptor was also examined. Extended analogue Pro-Leu-Deg-NH2 was the most active compound of this series. It was 10 times more potent and almost 2 times more effective than 1 in increasing apomorphine-induced rotations (56 +/- 15% at 1.0 mg/kg ip) and in enhancing [H-3]NPA specific binding (40%).

  DOI：

  10.1021/jm980656r
• 作为试剂：
  描述：

  环亮氨酸 、 、 sodium hydroxide 、 盐酸 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 1-羟基苯并三唑 、 氨 、 在 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 1-tent-Butoxycarbonylamino-cyclopentanecarboxylic acid 、 1-amino-cyclopentanecarboxylic acid amide hydrochloride salt 作用下， 以 水 、 二氯甲烷 为溶剂， 反应 32.5h， 以to afford 5j (0.45 g, 34% over three steps)的产率得到1-amino-cyclopentanecarboxylic acid amide hydrochloride salt
  参考文献：
  名称：

  Imidazol-4-one and Imidazole-4-thione Compounds

  摘要：

  本发明涉及公式（I）的咪唑-4-酮或咪唑-4-硫酮化合物，其中X、R1、R2、R3、R4、R5和R6如本文所定义。本发明还揭示了使用这些化合物治疗大麻素受体介导的疾病的方法。

  公开号：

  US20100113546A1

文献信息

• [EN] IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'IMIDAZOLINONE EN TANT QU'ANTAGONISTES DE RÉCEPTEURS CGRP
  申请人：MERCK SHARP & DOHME

  公开号：WO2010077752A1

  公开（公告）日：2010-07-08

  The present invention is directed to imidazolinone derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及嘧啶啉酮衍生物，其为CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，如偏头痛。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗涉及CGRP的这类疾病中使用这些化合物和组合物。
• [EN] 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS<br/>[FR] 3- ET 6-QUINOLINES AVEC ANTAGONISTES DE RÉCEPTEURS DE PEPTIDES ASSOCIÉS AU GÈNE DE LA CALCITONINE HÉTÉROCYCLIQUE À N LIAISONS
  申请人：MERCK SHARP & DOHME

  公开号：WO2010021919A1

  公开（公告）日：2010-02-25

  Compounds of Formula (I): (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.

  公式（I）的化合物：（其中变量R1A、R1B、R2、R3、R4、A和Z的定义如下），这些化合物可用作CGRP受体的拮抗剂，并且在治疗或预防涉及CGRP受体的疾病方面具有用处，例如头痛，特别是偏头痛和集群头痛。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP受体的这类疾病中的用途。
• 3- AND 6-QUINOLINES WITH N-ATTACHED HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Wood Michael R.

  公开号：US20110306604A1

  公开（公告）日：2011-12-15

  Compounds of Formula (I): (where variables R 1A , R 1B , R 2 , R 3 , R 4 , A, and Z are as defined herein) which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.

  公式(I)的化合物：（其中变量R1A，R1B，R2，R3，R4，A和Z的定义如本文所述），可用作CGRP受体的拮抗剂，对于治疗或预防CGRP受体参与的疾病，如头痛，尤其是偏头痛和集群头痛非常有用。本发明还涉及包含这些化合物的制药组合物，以及在预防或治疗CGRP受体参与的上述疾病方面使用这些化合物和组合物。
• IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS
  申请人：Selnick Harold G.

  公开号：US20110306626A1

  公开（公告）日：2011-12-15

  The present invention is directed to imidazolinone derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  本发明涉及咪唑啉酮衍生物，其是CGRP受体拮抗剂，可用于治疗或预防涉及CGRP的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗涉及CGRP的这些疾病中使用这些化合物和组合物的用途。
• BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS
  申请人：Jia Zhaozhong J.

  公开号：US20120142671A1

  公开（公告）日：2012-06-07

  The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of Syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition Syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by Syk kinase activity, such as Non Hodgkin's Lymphoma.

  本发明涉及公式I的化合物及其药学上可接受的盐、酯和前药，这些化合物是Syk激酶的抑制剂。本发明还涉及用于制备这些化合物的中间体，制备这种化合物的方法，含有这种化合物的药物组合物，抑制Syk激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗至少部分由Syk激酶活性介导的多种疾病，如非霍奇金淋巴瘤的方法。